Holen Sie sich die Stockscreener-App
20.44
3.40%
0.59
Schlusskurs vom Vortag:
$19.85
Offen:
$19.95
24-Stunden-Volumen:
40,083
Relative Volume:
0.16
Marktkapitalisierung:
$893.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.81
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
+12.71%
1M Leistung:
+3.35%
6M Leistung:
-25.71%
1J Leistung:
-2.22%
1-Tages-Spanne:
$19.65
$20.68
1-Wochen-Bereich:
$17.81
$20.68
52-Wochen-Spanne:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.48 | 893.49M | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.55 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.85 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
651.71 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.66 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.18 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling - Defense World
JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven (ELVN) Gains Attention as EHA Data Release Approaches | - GuruFocus
Trading (ELVN) With Integrated Risk Controls - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Lowered by Legal & General Group Plc - Defense World
Enliven Therapeutics chief scientific officer sells $80,365 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $80,365 in stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics Inc (ELVN) shows promising results - uspostnews.com
Enliven Therapeutics: Awaiting Additional Trial Data (NASDAQ:ELVN) - Seeking Alpha
Geode Capital Management LLC Acquires 12,510 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Can you now get a good deal on Enliven Therapeutics Inc’s shares? - uspostnews.com
(ELVN) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Boosted by Wellington Management Group LLP - Defense World
KLP Kapitalforvaltning AS Makes New $97,000 Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Ratios Revealed: Decoding Enliven Therapeutics Inc (ELVN)’s Financial Health - DWinneX
Corebridge Financial Inc. Trims Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics COO Anish Patel sells shares worth $120,268 By Investing.com - Investing.com India
Enliven Therapeutics COO Anish Patel sells shares worth $120,268 - Investing.com Australia
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - MSN
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - StreetInsider
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% After Insider Selling - Defense World
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock By Investing.com - Investing.com UK
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock - Investing.com
Where are the Opportunities in (ELVN) - news.stocktradersdaily.com
Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India
Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Lifesci Capital Issues Optimistic Forecast for ELVN Earnings - Defense World
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock - Investing.com
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com
Enliven grew fourth-quarter R&D spending with trials underway - BizWest
Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value The Markets
Enliven Therapeutics Reports 2024 Financial Results - TipRanks
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune
Enliven Therapeutics Inc. (ELVN) reports earnings - Quartz
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings - Nasdaq
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):